SINE

FORUS Therapeutics Inc and the Pan-Canadian Pharmaceutical Alliance (pCPA) Complete Negotiations for XPOVIO(R)(selinexor)

Retrieved on: 
수요일, 5월 24, 2023
Letter of intent, Nuclear transport, PCPA, Multiple myeloma, XPO1, Myeloma Canada, SINE, Pan-Canadian Pharmaceutical Alliance, Dexamethasone, LOI, Bortezomib, Patient, Master of Science, News, Health insurance, Pharmaceutical industry

Oakville, Ontario--(Newsfile Corp. - May 24, 2023) - FORUS Therapeutics Inc ("FORUS") and the pan-Canadian Pharmaceutical Alliance ("pCPA") have completed negotiations with a Letter of Intent (LOI) for XPOVIO®(selinexor) in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma (MM) who have received at least one prior therapy.

Key Points: 
  • Oakville, Ontario--(Newsfile Corp. - May 24, 2023) - FORUS Therapeutics Inc ("FORUS") and the pan-Canadian Pharmaceutical Alliance ("pCPA") have completed negotiations with a Letter of Intent (LOI) for XPOVIO®(selinexor) in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma (MM) who have received at least one prior therapy.
  • This is a significant milestone to ensure that Canadian MM patients have broad and equitable access to XPOVIO," said Kevin Leshuk, President and CEO of FORUS.
  • "This is exciting news for the MM community across Canada," said Martine Elias, MSc, Executive Director, Myeloma Canada.
  • This new treatment regimen provides patients with a unique, effective oral option and meets many of the treatment needs of the myeloma patient community."

Karyopharm to Participate at Upcoming Investor Conferences

Retrieved on: 
화요일, 11월 8, 2022
Endometrial cancer, NASDAQ, Microdeletion syndrome, Industry, KPTI, Company, Multiple myeloma, SINE, United Kingdom, View, Ruxolitinib, Science, XPO1, Multimedia, Pharmaceutical industry, Online shopping

Karyopharm Therapeutics Inc. (NASDAQ: KPTI) is a commercial-stage pharmaceutical company pioneering novel cancer therapies.

Key Points: 
  • Karyopharm Therapeutics Inc. (NASDAQ: KPTI) is a commercial-stage pharmaceutical company pioneering novel cancer therapies.
  • Karyopharm has a focused pipeline targeting multiple high unmet need cancer indications, including in multiple myeloma, endometrial cancer, myelodysplastic syndromes and myelofibrosis.
  • For more information about our people, science and pipeline, please visit www.karyopharm.com , and follow us on Twitter at @Karyopharm and LinkedIn .
  • XPOVIO and NEXPOVIO are registered trademarks of Karyopharm Therapeutics Inc.
    View original content to download multimedia: https://www.prnewswire.com/news-releases/karyopharm-to-participate-at-up...

Karyopharm to Report Third Quarter 2022 Financial Results on November 3, 2022

Retrieved on: 
목요일, 10월 20, 2022
LinkedIn, Therapy, Conference, Science, Multiple myeloma, Microdeletion syndrome, Twitter, Ruxolitinib, Multimedia, KPTI, Nasdaq, Endometrial cancer, Company, Industry, SINE, XPO1, View, Pharmaceutical industry

NEWTON, Mass., Oct. 20, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report third quarter 2022 financial results on Thursday, November 3, 2022. Karyopharm's management team will host a conference call and audio webcast at 4:30 p.m. ET on Thursday, November 3, 2022, to discuss the financial results and other company updates.

Key Points: 
  • ET --
    NEWTON, Mass., Oct.20, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report third quarter 2022 financial results on Thursday, November 3, 2022.
  • ET on Thursday, November 3, 2022, to discuss the financial results and other company updates.
  • For more information about our people, science and pipeline, please visit www.karyopharm.com , and follow us on Twitter at @Karyopharm and LinkedIn.
  • XPOVIOand NEXPOVIOare registered trademarks of Karyopharm Therapeutics Inc.
    View original content to download multimedia: https://www.prnewswire.com/news-releases/karyopharm-to-report-third-quar...

Karyopharm to Participate at Upcoming Investor Conferences

Retrieved on: 
수요일, 9월 7, 2022
SINE, Ruxolitinib, Endometrial cancer, View, KPTI, XPO1, Multiple myeloma, LinkedIn, Science, Microdeletion syndrome, Multimedia, Nasdaq, Company, Twitter, United Kingdom, Industry, Pharmaceutical industry, Online shopping

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company pioneering novel cancer therapies.

Key Points: 
  • Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company pioneering novel cancer therapies.
  • Karyopharm has a focused pipeline targeting multiple high unmet need cancer indications, including in multiple myeloma, endometrial cancer, myelodysplastic syndromes and myelofibrosis.
  • For more information about our people, science and pipeline, please visit www.karyopharm.com , and follow us on Twitter at @Karyopharm and LinkedIn .
  • XPOVIO and NEXPOVIO are registered trademarks of Karyopharm Therapeutics Inc. Any other trademarks referred to in this release are the property of their respective owners.

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
목요일, 9월 1, 2022
RSU, SINE, Ruxolitinib, Endometrial cancer, View, KPTI, XPO1, Multiple myeloma, Board, LinkedIn, Science, Microdeletion syndrome, Multimedia, Financial compensation, Nasdaq, Company, Twitter, United Kingdom, Industry, Employment, Pharmaceutical industry

Each of these equity awards were granted pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • Each of these equity awards were granted pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4).
  • Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company pioneering novel cancer therapies.
  • For more information about our people, science and pipeline, please visit www.karyopharm.com , and follow us on Twitter at @Karyopharm and LinkedIn.
  • XPOVIO and NEXPOVIO are registered trademarks of Karyopharm Therapeutics Inc.
    View original content to download multimedia: https://www.prnewswire.com/news-releases/karyopharm-therapeutics-reports...

Bidgely Selected as the Technology Service Provider for Energy Theft Solution By Ministry of Power, Gol in ‘Powerthon 2022’

Retrieved on: 
월요일, 8월 22, 2022
Software, Internet, Other Energy, Professional Services, Utilities, Data Management, Energy, Technology, Artificial Intelligence, Environment, Data Analytics, Green Technology, General of the branch, Congruent number, Machine learning, SINE, Workforce, Ministry, CEO, Technology, National Data Sharing and Accessibility Policy – Government of India, TOU, DDUGJY, IIT Bombay, ERP, Research, Artificial intelligence, PVS, QA, State, Forecasting, Time, Personality, Behavior, DER, MOP, GOI, Intelligence, Anomaly, Blog, Ministry of Power (India), Multimedia, Data science, Ministry of Power, Metre, REC, World Bank, Software as a service, Running, Public sector, Electricity, Public, REC Limited, EV, Silicon, Efficiency, RDSS, TSP, World, Computer data storage, Renewable energy, Ujwal DISCOM Assurance Yojana

(Graphic: Business Wire)

Key Points: 
  • (Graphic: Business Wire)
    Bidgely's newly launched Energy Theft Solution will demonstrate how AI-enabled data analytics can detect and resolve Indias energy misuse issues during a 4-month engagement with a state utility.
  • Congruently, Bidgely is working with a large utility in central India in collaboration with the World Bank to further prove theft detection analytics use cases.
  • Based on industry-leading non-intrusive load monitoring technology and advanced data analytics, Bidgelys Energy Theft Solution disaggregates customers energy consumption down to the appliance level.
  • To learn more about Bidgelys Energy Theft Solution for detecting energy misuse, visit bidgely.com/solutions/energy-theft-detection/ .

Karyopharm to Participate at the 2022 Wedbush Pacgrow Healthcare Conference

Retrieved on: 
화요일, 8월 2, 2022
Endometrial cancer, United Kingdom, Industry, Twitter, KPTI, Ruxolitinib, Multiple myeloma, Conference, SINE, Company, XPO1, Science, LinkedIn, Nasdaq, Microdeletion syndrome, Pharmaceutical industry

NEWTON, Mass., Aug. 2, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate in a fireside chat at the 2022 Wedbush Pacgrow Healthcare Conference.

Key Points: 
  • NEWTON, Mass., Aug. 2, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate in a fireside chat at the 2022 Wedbush Pacgrow Healthcare Conference.
  • The conference is being conducted in a virtual format and the fireside chat will take place on Tuesday, August 9, 2022 at 4:05 p.m.
  • Karyopharm has a focused pipeline targeting multiple high unmet need cancer indications, including in multiple myeloma, endometrial cancer, myelodysplastic syndromes and myelofibrosis.
  • For more information about our people, science and pipeline, please visit www.karyopharm.com , and follow us on Twitter at @Karyopharm and LinkedIn .

Karyopharm to Report Second Quarter 2022 Financial Results on August 4, 2022

Retrieved on: 
목요일, 7월 28, 2022
Endometrial cancer, United Kingdom, Industry, Twitter, KPTI, Ruxolitinib, Therapy, Multiple myeloma, NASDAQ, Conference, SINE, Company, XPO1, Science, LinkedIn, Microdeletion syndrome, Pharmaceutical industry

NEWTON, Mass., July 28, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report second quarter 2022 financial results on Thursday, August 4, 2022. Karyopharm's management team will host a conference call and audio webcast at 8:00 a.m. ET on Thursday, August 4, 2022, to discuss the financial results and other company updates.

Key Points: 
  • ET --
    NEWTON, Mass., July 28, 2022 /PRNewswire/ --Karyopharm Therapeutics Inc. (NASDAQ: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report second quarter 2022 financial results on Thursday, August 4, 2022.
  • ET on Thursday, August 4, 2022, to discuss the financial results and other company updates.
  • Karyopharm has a focused pipeline targeting multiple high unmet need cancer indications, including in multiple myeloma, endometrial cancer, myelodysplastic syndromes and myelofibrosis.
  • For more information about our people, science and pipeline, please visit www.karyopharm.com , and follow us on Twitter at @Karyopharm and LinkedIn .

FORUS Therapeutics Inc ("FORUS") Announces XPOVIO® (selinexor) Is Authorized for Sale by Health Canada

Retrieved on: 
화요일, 6월 7, 2022
MM, Life, Oncology, Caregiver, Adult, Multiple myeloma, Radical behaviorism, Lymphatic system, CEO, Professor, Disease, Plasma cell, Solution, Physician, Sale, Tumor suppressor gene, Therapy, Growth, Bortezomib, Master of Science, Health Canada, Myeloma Canada, Patient, Program, B cell, XPO1, Immune system, Antibody, SINE, Dexamethasone, Department, Princess Margaret Cancer Centre, Bone marrow, Hematology, Cancer, Pharmaceutical industry

This is the first regulatory approval for XPOVIO in Canada in multiple myeloma and follows recent approvals in Australia, China, South Korea, Singapore and the United States.

Key Points: 
  • This is the first regulatory approval for XPOVIO in Canada in multiple myeloma and follows recent approvals in Australia, China, South Korea, Singapore and the United States.
  • "The FORUS team is very proud to launch XPOVIO in Canada and bring forth a novel and effective addition to existing regimens for the treatment of relapsed or refractory multiple myeloma.
  • XPOVIO is a registered trademark of Karyopharm Therapeutics Inc. and is used by FORUS Therapeutics Inc. under license.
  • FORUS Therapeutics is a Canadian biopharmaceutical company dedicated to advancing differentiated, novel medicines for hematologic malignancies and other forms of cancer.

Karyopharm to Participate at the Jefferies Healthcare Conference

Retrieved on: 
수요일, 6월 1, 2022
United Kingdom, Science, Company, KPTI, Endometrial cancer, Conference, Ruxolitinib, LinkedIn, Multiple myeloma, Microdeletion syndrome, Nasdaq, XPO1, SINE, Twitter, Industry, Pharmaceutical industry

NEWTON, Mass., June 1, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate in a fireside chat at the Jefferies Healthcare Conference on Thursday, June 9, 2022 at 9:30 a.m.

Key Points: 
  • NEWTON, Mass., June 1, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate in a fireside chat at the Jefferies Healthcare Conference on Thursday, June 9, 2022 at 9:30 a.m.
  • Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company pioneering novel cancer therapies.
  • Karyopharm has a focused pipeline targeting multiple high unmet need cancer indications, including in multiple myeloma, endometrial cancer, myelodysplastic syndromes and myelofibrosis.
  • For more information about our people, science and pipeline, please visit www.karyopharm.com , and follow us on Twitter at @Karyopharm and LinkedIn .